This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schmielau, J. Articles by Finn, O. J. Search for Related Content PubMed PubMed Citation Articles by Schmielau, J. Articles by Finn, O. J.

Activated Granulocytes and Granulocyte-derived Hydrogen Peroxide Are the Underlying Mechanism of Suppression of T-Cell Function in Advanced Cancer Patients¹

Department of Molecular Genetics and Biochemistry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261

	ABSTRACT

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Impaired T-cell function in patients with advanced cancer has been a widely acknowledged finding, but mechanisms reported thus far are those primarily operating in the tumor microenvironment. Very few mechanisms have been put forth to explain several well-described defects in peripheral blood T cells, such as reduction in expression of signaling molecules, decreased production of cytokines, or increased apoptosis. We have closely examined the peripheral blood mononuclear cell (PBMC) samples derived from patients and healthy individuals, and we have observed an important difference that may underlie the majority of reported defects. We observed that in samples from patients only, an unusually large number of granulocytes copurify with low density PBMCs on a density gradient rather than sediment, as expected, to the bottom of the gradient. We also show that activating granulocytes from a healthy donor with N-formyl-L-methionyl-L-leucyl-L-phenylalanine could also cause them to sediment aberrantly and copurify with PBMCs, suggesting that density change is a marker of their activation. To confirm this, we looked for other evidence of in vivo granulocyte activation and found it in drastically elevated plasma levels of 8-isoprostane, a product of lipid peroxidation and a marker of oxidative stress. Reduced T-cell receptor chain expression and decreased cytokine production by patients’ T cells correlated with the presence of activated granulocytes in their PBMCs. We showed that freshly obtained granulocytes from healthy donors, if activated, can also inhibit cytokine production by T cells. This action is abrogated by the addition of the hydrogen peroxide (H₂O₂) scavenger, catalase, implicating H₂O₂ as the effector molecule. Indeed, when added alone, H₂O₂ could suppress cytokine production of normal T cells. These findings indicate that granulocytes are activated in advanced cancer patients and that granulocyte-derived H₂O₂ is the major cause of severe systemic T-cell suppression.

	INTRODUCTION

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Despite increasing efforts, studies into tumor-induced immunosuppression have not provided plausible mechanisms that would explain the severe functional impairment in all circulating T cells seen in patients with advanced cancer (1) . Although a growing number of tumor-specific antigens are being identified as potential targets that could be recognized by the immune system, cancer patients largely fail to mount an effective immune response against them. A failed T-cell response early in tumor development appears to be predominantly antigen specific (2) . In some instances, tumor antigens are not sufficiently processed or presented to T cells because of the nature of the particular antigen (3) or defects in antigen-presenting cells (4) . It has also been reported that proliferation of tumor-specific T cells could be hindered or the tumor-specific response could be switched to an unfavorable Th2³ that does not support development of cytotoxic effector T cells from precursors stimulated at the tumor site (5) . Even if competent T cells are made and capable of infiltrating the tumor, it has been reported that they can undergo apoptosis induced by Fas ligand expressed on the tumor cells (6) . Although these mechanisms might explain tumor-specific immunosuppression, they are often restricted to the immediate tumor environment and fail to explain the more generalized immunosuppression that develops with tumor progression when patients stop responding even to common recall antigens (7) . The first molecular mechanism described that potentially underlies these defects is the reduced expression of the TCR chain and TCR-associated protein tyrosine kinases in splenocytes from tumor-bearing mice (8) . Subsequent studies with cancer patients indeed showed a reduced TCR chain expression that correlated with the tumor state of the patient (9, 10, 11) . This defect was later correlated with antitumor responses in melanoma patients who underwent immunotherapy with IL-2 (12) . Recently, one possible reason for these defects in TCR expression has been proposed to be the absence of L-arginine, known to be depleted in certain disease states (13) and accompanied by a decrease in T-cell proliferation (14 , 15) . A defect in the translocation of transcription factors in T cells, such as nuclear factor-B, has been demonstrated and implicated in tumor-induced suppression (9 , 16) . As a likely consequence of both defects, an impaired cytokine production by T cells has been shown in patients with a variety of tumors (5 , 17, 18, 19, 20, 21) . Circulating suppressor cells or suppressor factors have been postulated as the cause for some of these defects in T-cell function. One type of candidate suppressor cells investigated have been the macrophages that can undergo activation in the vicinity of the tumor and produce factors, such as H₂O₂, that suppress various other immune effector cells (22) . Macrophages, however, are not circulating cells, and their suppressive function is still expected to be limited to the effector cells in the tumor microenvironment.

Here we propose a mechanism that likely underlies all of the others described thus far and that we consider the common cause for most of the observed defects in immune function in advanced cancer patients. This mechanism involves activation of granulocytes and oxidative stress mediated by H₂O₂ that they produce. Unlike macrophages that are primarily found in tissues, granulocytes are abundantly present in circulation. Phagocytosis by granulocytes is supported by an oxidative burst that releases reactive oxygen species from membrane-bound enzymes and facilitates killing of microorganisms. We offer evidence of in vivo granulocyte activation in cancer patients that correlates with the inhibition of TCR chain expression and cytokine production by their T cells. We show that coincubation of T cells with activated granulocytes in vitro leads to the inhibition of cytokine production and that the mediator of that inhibition is H₂O₂.

	MATERIALS AND METHODS

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Blood Samples.
Blood samples were obtained under an Institutional Review Board-approved protocol from patients with metastatic adenocarcinomas of the pancreas, colon, and breast, seen at the University of Pittsburgh Cancer Institute. All radiation or chemotherapy had been concluded at least 4 weeks prior to the blood drawing. PBMCs were purified on a density gradient using a lymphocyte separation medium (ICN, Aurora, OH) and stored at -80°C in fetal bovine serum containing medium with 10% DMSO.

Granulocyte and T-Cell Assays.
Granulocytes were purified from peripheral blood with dextran sedimentation as described (23) . PBMCs were collected by centrifugation in lymphocyte separation medium (ICN), and residual RBCs were lysed in a hypotonic saline solution. To obtain activated granulocytes, whole blood was incubated for 1 h with FMLP (Sigma Chemical Co., St. Louis, MO) prior to density gradient centrifugation. Cells were stained with anti-CD15 antibody (Becton Dickinson, Mountain View, CA) for flow cytometry or used for cytospins stained with Diff-Quick (Baxter, McGraw Park, IL). T cells were activated for 4 h with 20 µg/ml PMA and 1 µM ionomycin (Sigma Chemical Co.).

PBMC samples were analyzed for TCR expression and cytokine production by flow cytometry as described (24) . For intracellular cytokine staining, 2 mM monensin (Sigma Chemical Co.) was added to T cells for 4 h. Cells were fixed with 2% PFA³ and permeabilized with FACS buffer (PBS supplemented with 5% FBS and 0.1% sodium azide) containing 0.1% saponin (all from Sigma Chemical Co.). An anti-TCR chain antibody, TCR-, TIA-2 (Coulter, Fullerton, CA) was used for indirect staining prior to a secondary goat antimouse R-phycoerythrin-conjugated antibody (Biosource, Camarillo, CA). Antibodies against the cytokines IFN-, TNF-, IL-2, or IL-4 were obtained from PharMingen (San Diego, CA). Live cells were stained with antibodies against CD11b, CD14, and CD15 on granulocytes and monocytes and antibodies against CD3 and CD8 (Becton Dickinson) on T cells. Analysis was done on a FACS-Calibur (Becton Dickinson).

For granulocyte/T-cell coculture assays, both cell types were purified from the same blood sample. Granulocytes (4 x 10⁶) were seeded into the lower compartment of a six-well transwell system (Costar, Cambridge, MA), and 2 x 10⁶ PBMCs were either placed into the upper compartment or directly mixed with the granulocytes in a final volume of 5 ml. The experiment, involving freezing, fixation, or addition of bovine catalase (Sigma Chemical Co.), was performed with 7.5 x 10⁵ T cells and granulocytes in a 24-well plate (Costar). Granulocytes were either frozen overnight in FBS with 10% DMSO at -80°C or fixed in 2% PFA/PBS for 20 min prior to the assay. For experiments involving H₂O₂, PBMCs were treated for 5 min, followed by an additional 5-min incubation with catalase at a final concentration of 1000 units/ml. Dose-response experiments with H₂O₂ were done in the absence of FBS.

Detection of F₂-Isoprostane
Plasma samples that had been stored at -80°C were used in an enzyme immunoassay that detects F₂-isoprostane (Cayman Chemical, Ann Arbor, MI). To measure total isoprostane, we hydrolyzed plasma samples with potassium hydroxide and performed detection after solid phase extraction with C₁₈ columns (Millipore, Milford, MA) as recommended by the manufacturer.

	RESULTS

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Evidence of in Vivo Granulocyte Activation and Oxidative Stress Damage in Cancer Patients.
Density gradient centrifugation has been traditionally used as a method to separate PBMCs, such as lymphocytes, from polymorphonuclear cells, such as granulocytes. Granulocytes are expected to sediment in the cell pellet because of their high buoyant density. We noticed that in the process of purification of blood from cancer patients (Fig. 1A) but not healthy controls (Fig. 1B) , unusually large numbers of granulocytes sedimented with the same density as PBMCs. This was detected by flow cytometry analysis of the composition of purified PBMCs by cell size and granularity and confirmed by staining with anti-CD15 antibody specific for granulocytes (Fig. 2) . We hypothesized that aberrant sedimentation of granulocytes could be a result of a change in their density attributable to activation. To reproduce these events in vitro, we treated whole blood from a healthy donor with FMLP, a peptide that induces receptor-mediated granulocyte activation (25) . An hour of treatment indeed led to aberrant granulocyte sedimentation. Granulocytes copurified with PBMCs in a FMLP dose-dependent manner (Fig. 2A) and represented up to 12.5% of the population, as confirmed by CD15 expression (Fig. 2B) and by specific morphology observed in the cytospins (Fig. 2, C and D) .

View larger version (25K): [in this window] [in a new window] [Download PPT slide]   Fig. 1. In cancer patients but not in normal controls, granulocytes copurify with PBMCs on a density gradient. A, PBMC sample from a cancer patient. B, PBMC sample from a healthy control. Blue, CD3+cells; purple, CD14+ cells; red, CD15+ cells; gray, other cells; SSC, side scatter; FSC, forward scatter.

View larger version (76K): [in this window] [in a new window] [Download PPT slide]   Fig. 2. Granulocytes that copurify with PBMCs from a healthy donor on a density gradient are activated. A, FMLP dose-dependent increase in percentage of granulocytes (CD15+) copurifying with PBMCs. B, peripheral blood incubated without (----) and with 1 µM FMLP () prior to density gradient centrifugation and tested for the presence of granulocytes (CD15). Cytospins of PBMCs purified before treatment (C) or after treatment (D) with FMLP.

2

View larger version (16K): [in this window] [in a new window] [Download PPT slide]   Fig. 4. TCR chain expression and IFN- production by T cells from cancer patients compared with healthy controls. A, mean fluorescence intensity of staining of all T cells from TCR chain expression shown as multiples of antibody isotype control. B, percentage of IFN--producing T cells among all T cells. Horizontal bars, median values.

View larger version (19K): [in this window] [in a new window] [Download PPT slide]   Fig. 3. Copurification of activated granulocytes with PBMCs, white blood count, and signs of oxidative stress. In A, CD15+ cells copurified with PBMCs in patients compared with healthy controls. B, absolute neutrophil count in peripheral blood of patients. C, absolute lymphocytes count in peripheral blood of patients. D, plasma levels of isoprostane in patients. Normal ranges are marked with a rectangle.

Reduced TCR Expression and Cytokine Production in Peripheral Blood T Cells.

Granulocyte-derived Hydrogen Peroxide Inhibits Cytokine Production.
The observation that suppression of the TCR chain expression and T-cell cytokine production coincided with signs of granulocyte activation and elevated isoprostane plasma levels in cancer patients encouraged us to seek a direct proof that activated granulocytes can be responsible for inhibition of T-cell function. We purified granulocytes from healthy donor blood by density sedimentation and obtained a >90% pure population as confirmed by CD15 expression (data not shown). We mixed these granulocytes with lymphocytes from the same donor and coincubated them under different conditions (Fig. 5A) . In the absence of granulocytes, >30% of T cells produced IFN- when activated with PMA and ionomycin. Coactivation of lymphocytes and granulocytes had a strong inhibitory effect on IFN- production by T cells. Coactivation in a transwell system, where granulocytes and lymphocytes were separated by a membrane, showed that inhibition may be caused by soluble factors. The integrity of the granulocytes was important for this inhibition inasmuch as either fixation with paraformaldehyde or freezing greatly reduced their inhibitory effect (Fig. 5B) .

View larger version (21K): [in this window] [in a new window] [Download PPT slide]   Fig. 5. Granulocyte-mediated inhibition of cytokine production in vitro. A, IFN--producing T cells in the absence or presence of granulocytes in a transwell system (membrane) or in direct contact (direct). B, IFN--producing T cells in the absence or presence of untreated (Ø), PFA-fixed (fixed), or frozen and thawed (frozen) granulocytes. C, percentage of IFN--producing T cells after activation, in PBMCs from patients (•) and healthy controls (), plotted against the percentage of contaminating granulocytes. The regression line for patient samples is shown with the 95% confidence interval (P = 0.006; slope, -29.6 ± 9.9). D, increase in the percentage of IFN--producing T cells in the presence of catalase. Dose-dependent inhibition by hydrogen peroxide of IFN- (•), TFN- (), and IL-2 () (E) and IL-4 () producing T cells (F) is shown.

Granulocytes limit tissue destruction by releasing protecting enzymes such as superoxide dismutase and catalase. Superoxide dismutase converts superoxide anion to H₂O₂, which in turn is degraded to water by catalase. When we added increasing concentrations of catalase to the cocultures of granulocytes and lymphocytes, most of the inhibition of IFN- production was abrogated (Fig. 5D) . This identified H₂O₂ as the effector molecule mediating inhibition of this T-cell function. Adding H₂O₂ directly to T cells resulted in a reduced number of cytokine-producing cells, not only for IFN- but also TNF-, IL-2, and IL-4, in a dose-dependent manner (Fig. 5, E and F) .

	DISCUSSION

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
We have provided evidence here for one mechanism that underlies several well-described defects in T-cell function in patients with advanced cancer. We show that cancer patients respond to the presence of the tumor with activation of granulocytes. This is likely an attempt on the part of the innate immune system to protect the organism. The chronic presence of the tumor and thus chronic activation of granulocytes with the accompanying production of H₂O₂ results, ironically, in the suppression of the adaptive immune functions. Here we show specifically that the release of reactive oxygen species during the oxidative burst of granulocytes, i.e., H₂O₂, is the major contributor to a systemic T-cell dysfunction. This is supported by the observation that cancer patients showed signs of extensive granulocyte activation with massive elevation of plasma levels of 8-isoprostane, a product of lipid oxidation and a marker for oxidative stress, that exceeded measurements found in other diseases with documented oxidative stress (26, 27, 28) .

Our in vitro experiments demonstrated directly that coincubation of granulocytes and lymphocytes could inhibit cytokine production but required the functional integrity and activation of granulocytes. The observation that granulocyte-mediated inhibition of cytokine production could be abrogated by the addition of catalase to inhibit H₂O₂ identified this product as the major soluble mediator of activated granulocyte effects. We confirmed this by adding H₂O₂ to T cells and inducing potent inhibition of cytokine production in a dose-dependent manner. Analyzing ex vivo cytokine production by patients’ T cells, we found that the inhibition was most pronounced for IFN- and, although not significant, was also detectable for IL-4. We did not detect a switch from Th1 cytokines, which promote cell-mediated cytotoxicity, toward an antibody-mediated Th2-dominated responses. A decrease in cytokine production of T cells significantly correlated with the number of circulating activated granulocytes.

The activation of granulocytes could be induced by an inflammatory response or cytokines produced by the tumor. Tumor cells are known to secrete cytokines, among them are cytokines that affect granulocytes (29 , 30) . Possible candidates are TNF- and IL-8, which could be elevated in the serum of cancer patients (30 , 31) and stimulate the oxidative burst (32 , 33) . Although we have concentrated on documenting immunosuppressive effects on T cells, it is highly probable that other cells of the immune system could be equally affected by the same mediators of oxidative stress. A decrease in the function of NK cells mediated by H₂O₂ has been documented (22) , whereas causes of defects in the function of dendritic cells are unknown (4) . Little is known about the functional competence of B cells in cancer patients, but B cells might be affected in a similar manner to the T cells. Our data suggest that inhibition of the oxidative burst of granulocytes might be a useful treatment of cancer patients prior to attempting any form of immunotherapy.

	FOOTNOTES

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ Supported by a grant from the "Deutsche Krebshilfe" (to J. S.) and NIH Grant RO1 CA56103 and a grant from The Nathan Arenson Fund for Pancreatic Cancer Research (to O. J. F.).

² To whom requests for reprints should be addressed, at Medizinische Universitätsklinik, Knappschaftskrankenhaus, In der Schornau 23–25, 44892 Bochum, Germany. E-mail: jan.schmielau{at}ruhr-uni-bochum.de

³ The abbreviations used are: Th1 and Th2, T helper types 1 and 2; TCR, T-cell receptor; IL, interleukin; PBMC, peripheral blood mononuclear cell; FMLP, N-formyl-L-methionyl-L-leucyl-L-phenylalanine; PMA, phorbol myristate acetate; TNF, tumor necrosis factor; PFA, paraformaldehyde.

Received 12/15/00. Accepted 4/11/01.

	REFERENCES

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 

1. Finke J., Ferrone S., Frey A., Mufson A., Ochoa A. Where have all the T cells gone? Mechanisms of immune evasion by tumors. Immunol. Today, 20: 158-160, 1999.[Medline]
2. Staveley-O’Carroll K., Sotomayor E., Montgomery J., Borrello I., Hwang L., Fein S., Pardoll D., Levitsky H. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA, 95: 1178-1183, 1998.[Abstract/Free Full Text]
3. Hiltbold E. M., Vlad A. M., Ciborowski P., Watkins S. C., Finn O. J. The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells. J. Immunol., 165: 3730-3741, 2000.[Abstract/Free Full Text]
4. Esche C., Lokshin A., Shurin G. V., Gastman B. R., Rabinowich H., Watkins S. C., Lotze M. T., Shurin M. R. Tumor’s other immune targets: dendritic cells. J. Leukocyte Biol., 66: 336-344, 1999.[Abstract]
5. Goto S., Sato M., Kaneko R., Itoh M., Sato S., Takeuchi S. Analysis of Th1 and Th2 cytokine production by peripheral blood mononuclear cells as a parameter of immunological dysfunction in advanced cancer patients. Cancer Immunol. Immunother., 48: 435-442, 1999.[Medline]
6. Strand S., Hofmann W. J., Hug H., Muller M., Otto G., Strand D., Mariani S. M., Stremmel W., Krammer P. H., Galle P. R. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells–a mechanism of immune evasion?. Nat. Med., 2: 1361-1366, 1996.[Medline]
7. Young R. C., Corder M. P., Haynes H. A., DeVita V. T. Delayed hypersensitivity in Hodgkin’s disease. Am. J. Med., 52: 63-72, 1972.[Medline]
8. Mizoguchi H., O’Shea J. J., Longo D. L., Loeffler C. M., McVicar D. W., Ochoa A. C. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science (Wash. DC), 258: 1795-1798, 1992.[Abstract/Free Full Text]
9. Finke J. H., Zea A. H., Stanley J., Longo D. L., Mizoguchi H., Tubbs R. R., Wiltrout R. H., O’Shea J. J., Kudoh S., Klein E., Bukowski R. M., Ochoa A. C. Loss of T-cell receptor chain and p56^lck in T-cells infiltrating human renal cell carcinoma. Cancer Res., 53: 5613-5616, 1993.[Abstract/Free Full Text]
10. Nakagomi H., Peterson M., Magnusson I., Matsuda M., Mellstedt H., Taupin J-L., Vivier E., Anderson P., Kiessling R. Decreased expression of the signal-transducing chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res., 53: 5610-5612, 1993.[Abstract/Free Full Text]
11. Gunji Y., Hori S., Aoe T., Asano T., Ochiai T., Isona K., Saito T. High frequency of cancer patients with abnormal assembly of the T cell receptor-CD3 complex in peripheral blood T lymphocytes. Jpn. J. Cancer Res., 85: 1189-1192, 1994.[Medline]
12. Rabinowich H., Banks M., Reichert T. E., Logan T. F., Kirkwood J. M., Whiteside T. L. Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin therapy. Clin. Cancer Res., 2: 1263-1274, 1996.[Abstract]
13. Taheri F., Ochoa J. B., Faghiri Z., Culotta K., Park H.-J., Lan M. S., Zea A. H., Ochoa A. C. L-Arginine regulates the expression of the T cell receptor chain (CD3) in Jurkat cells. Clin. Cancer Res., 7: 958s-965s, 2001.
14. Roth E., Steininger R., Winkler S., Langle F., Grunberger T., Fugger R., Muhlbacher F. L-Arginine deficiency after liver transplantation as an effect of arginase efflux from the graft. Influence on nitric oxide metabolism. Transplantation, 57: 665-669, 1994.[Medline]
15. Ochoa J. B., Udekwu A. O., Billiar T. R., Curran R. D., Cerra F. B., Simmons R. L., Peitzman A. B. Nitrogen oxide levels in patients after trauma and during sepsis. Ann. Surg., 214: 621-626, 1991.[Medline]
16. Ghosh P., Sica A., Young H. A., Ye J., Franco J. L., Wiltrout R. H., Longo D. L., Rice N. R., Komschlies K. L. Alteration in NFB/Rel family proteins in splenic T-cells from tumor-bearing mice and reversal following therapy. Cancer Res., 54: 2969-2972, 1994.[Abstract/Free Full Text]
17. Elliott L. H., Brooks W. H., Roszman T. L. Cytokinetic basis for the impaired activation of lymphocytes from patients with primary intracranial tumors. J. Immunol., 132: 1208-1215, 1984.[Abstract]
18. Elsasser-Beile U., Kolble N., Grussenmeyer T., Schultze-Seemann W., Wetterauer U., Gallati H., Schulte Monting J., von Kleist S. Th1 and Th2 cytokine response patterns in leukocyte cultures of patients with urinary bladder, renal cell and prostate carcinomas. Tumour Biol., 19: 470-476, 1998.[Medline]
19. Guilloux Y., Viret C., Gervois N., Le Dréan E., Pandolfino M-C., Diez E., Jotereau F. Defective lymphokine production by most CD8⁺ and CD4⁺ tumor-specific T cell clones derived from human melanoma-infiltrating lymphocytes in response to autologous tumor cells in vitro. Eur. J. Immunol., 24: 1966-1973, 1994.[Medline]
20. Nieland J. D., Loviscek K., Kono K., Albain K. S., McCall A. R., Potkul R. K., Fisher S. G., Velders M. P., Petersson M., Kiessling R., Kast W. M. PBLs of early breast carcinoma patients with a high nuclear grade tumor unlike PBLs of cervical carcinoma patients do not show a decreased TCR expression but are functionally impaired. J. Immunother. Emphasis Tumor Immunol., 21: 317-322, 1998.
21. Zea A. H., Curti B. D., Longo D. L., Alvord W. G., Strobl S. L., Mizoguchi H., Creekmore S. P., O’Shea J. J., Powers G. C., Urba W. J., Ochoa A. C. Alterations in, T. cell receptor and signal transduction molecules in melanoma patients. Clin. Cancer Res., 1: 1327-1335, 1995.[Abstract]
22. Kono K., Salazar-Onfray F., Petersson M., Hansson J., Masucci G., Wasserman K., Nakazawa T., Anderson P., Kiessling R. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing molecules and inhibits tumor-specific T cell- and natural killer cell-mediated cytotoxicity. Eur. J. Immunol., 26: 1308-1313, 1996.[Medline]
23. Clark R. A., Nauseef W. M. Isolation and functional analysis of neutrophils Coligan J. E. Kruisbeek A. M. Margulies D. H. Shevach E. M. Stober W. eds. . Current Protocols in Immunology, : 7.23.1-7.17, John Wiley & Sons New York 1998.
24. Schmielau J., Nalesnik M. A., Finn O. J. Suppressed TCR chain expression and cytokine production in pancreatic cancer patients. Clin. Cancer Res., 7: 933s-939s, 2001.
25. Panaro M. A., Mitolo V. Cellular responses to FMLP challenging: a mini-review. Immunopharmacol. Immunotoxicol., 21: 397-419, 1999.[Medline]
26. Morrow J. D., Roberts L. J. The isoprostanes: unique bioactive products of lipid peroxidation. Prog. Lipid Res., 36: 1-21, 1997.[Medline]
27. Kluck R. M., Bossy-Wetzel E., Green D. R., Newmeyer D. D. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science (Wash. DC), 275: 1132-1136, 1997.[Abstract/Free Full Text]
28. Collins C. E., Quaggiotto P., Wood L., O’Loughlin E. V., Henry R. L., Garg M. L. Elevated plasma levels of F2 -isoprostane in cystic fibrosis. Lipids, 34: 551-556, 1999.[Medline]
29. Schmielau J., Kalthoff H., Roeder C., Schmiegel W. Cytokines and the biology of pancreatic cancer Neoptolemos J. Lemoine N. eds. . Pancreatic Cancer: Molecular and Clinical Advances, : 36-50, Blackwell Science London 1995.
30. Chen Z., Malhotra P. S., Thomas G. R., Ondrey F. G., Duffey D. C., Smith C. W., Enamorado I., Yeh N. T., Kroog G. S., Rudy S., McCullagh L., Mousa S., Quezado M., Herscher L. L., Van Waes C. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin. Cancer Res., 5: 1369-1379, 1999.[Abstract/Free Full Text]
31. Wu C. W., Chi C. W., Hsieh M. C., Chao M. F., Lui W. Y., P’Eng F. K. Serum tumor necrosis factor in patients with gastric cancer. Anticancer Res., 18: 1597-1599, 1998.[Medline]
32. Menegazzi R., Cramer R., Patriarca P., Scheurich P., Dri P. Evidence that tumor necrosis factor (TNF)-induced activation of neutrophil respiratory burst on biologic surfaces is mediated by the p55 TNF receptor. Blood, 84: 287-293, 1994.[Abstract/Free Full Text]
33. Jones S. A., Wolf M., Qin S., Mackay C. R., Baggiolini M. Different functions for the interleukin 8 receptors (IL-8R) of human neutrophil leukocytes: NADPH oxidase and phospholipase D are activated through IL-8R1 but not IL-8R2. Proc. Natl. Acad. Sci. USA, 93: 6682-6686, 1996.[Abstract/Free Full Text]

This article has been cited by other articles:

				K. Hagenow, K. A. Gelderman, M. Hultqvist, P. Merky, J. Backlund, O. Frey, T. Kamradt, and R. Holmdahl Ncf1-Associated Reduced Oxidative Burst Promotes IL-33R+ T Cell-Mediated Adjuvant-Free Arthritis in Mice J. Immunol., July 15, 2009; 183(2): 874 - 881. [Abstract] [Full Text] [PDF]

				T. J. Stewart, D. J. Liewehr, S. M. Steinberg, K. M. Greeneltch, and S. I. Abrams Modulating the Expression of IFN Regulatory Factor 8 Alters the Protumorigenic Behavior of CD11b+Gr-1+ Myeloid Cells J. Immunol., July 1, 2009; 183(1): 117 - 128. [Abstract] [Full Text] [PDF]

				S. K. Bunt, V. K. Clements, E. M. Hanson, P. Sinha, and S. Ostrand-Rosenberg Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4 J. Leukoc. Biol., June 1, 2009; 85(6): 996 - 1004. [Abstract] [Full Text] [PDF]

				S. Mandruzzato, S. Solito, E. Falisi, S. Francescato, V. Chiarion-Sileni, S. Mocellin, A. Zanon, C. R. Rossi, D. Nitti, V. Bronte, et al. IL4R{alpha}+ Myeloid-Derived Suppressor Cell Expansion in Cancer Patients J. Immunol., May 15, 2009; 182(10): 6562 - 6568. [Abstract] [Full Text] [PDF]

				J. S. Pufnock and J. L. Rothstein Oncoprotein Signaling Mediates Tumor-Specific Inflammation and Enhances Tumor Progression J. Immunol., May 1, 2009; 182(9): 5498 - 5506. [Abstract] [Full Text] [PDF]

				D. Mougiakakos, C. C. Johansson, and R. Kiessling Naturally occurring regulatory T cells show reduced sensitivity toward oxidative stress-induced cell death Blood, April 9, 2009; 113(15): 3542 - 3545. [Abstract] [Full Text] [PDF]

				J. S. Ko, A. H. Zea, B. I. Rini, J. L. Ireland, P. Elson, P. Cohen, A. Golshayan, P. A. Rayman, L. Wood, J. Garcia, et al. Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients Clin. Cancer Res., March 15, 2009; 15(6): 2148 - 2157. [Abstract] [Full Text] [PDF]

				P. C. Rodriguez, M. S. Ernstoff, C. Hernandez, M. Atkins, J. Zabaleta, R. Sierra, and A. C. Ochoa Arginase I-Producing Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma Are a Subpopulation of Activated Granulocytes Cancer Res., February 15, 2009; 69(4): 1553 - 1560. [Abstract] [Full Text] [PDF]

				T. Ando, K. Mimura, C. C. Johansson, M. G. Hanson, D. Mougiakakos, C. Larsson, T. Martins da Palma, D. Sakurai, H. Norell, M. Li, et al. Transduction with the Antioxidant Enzyme Catalase Protects Human T Cells against Oxidative Stress J. Immunol., December 15, 2008; 181(12): 8382 - 8390. [Abstract] [Full Text] [PDF]

				S. Kusmartsev, Z. Su, A. Heiser, J. Dannull, E. Eruslanov, H. Kubler, D. Yancey, P. Dahm, and J. Vieweg Reversal of Myeloid Cell-Mediated Immunosuppression in Patients with Metastatic Renal Cell Carcinoma Clin. Cancer Res., December 15, 2008; 14(24): 8270 - 8278. [Abstract] [Full Text] [PDF]

				H. van Cruijsen, A. A.M. van der Veldt, L. Vroling, D. Oosterhoff, H. J. Broxterman, R. J. Scheper, G. Giaccone, J. B.A.G. Haanen, A. J.M. van den Eertwegh, E. Boven, et al. Sunitinib-Induced Myeloid Lineage Redistribution in Renal Cell Cancer Patients: CD1c+ Dendritic Cell Frequency Predicts Progression-Free Survival Clin. Cancer Res., September 15, 2008; 14(18): 5884 - 5892. [Abstract] [Full Text] [PDF]

				S. Buonocore, N. O. Haddou, F. Moore, S. Florquin, F. Paulart, C. Heirman, K. Thielemans, M. Goldman, and V. Flamand Neutrophil-dependent tumor rejection and priming of tumoricidal CD8+ T cell response induced by dendritic cells overexpressing CD95L J. Leukoc. Biol., September 1, 2008; 84(3): 713 - 720. [Abstract] [Full Text] [PDF]

				S. Kusmartsev, E. Eruslanov, H. Kubler, T. Tseng, Y. Sakai, Z. Su, S. Kaliberov, A. Heiser, C. Rosser, P. Dahm, et al. Oxidative Stress Regulates Expression of VEGFR1 in Myeloid Cells: Link to Tumor-Induced Immune Suppression in Renal Cell Carcinoma J. Immunol., July 1, 2008; 181(1): 346 - 353. [Abstract] [Full Text] [PDF]

				O. J. Finn Cancer Immunology N. Engl. J. Med., June 19, 2008; 358(25): 2704 - 2715. [Full Text] [PDF]

				S. Nagaraj and D. I. Gabrilovich Tumor Escape Mechanism Governed by Myeloid-Derived Suppressor Cells Cancer Res., April 15, 2008; 68(8): 2561 - 2563. [Abstract] [Full Text] [PDF]

				K. Movahedi, M. Guilliams, J. Van den Bossche, R. Van den Bergh, C. Gysemans, A. Beschin, P. De Baetselier, and J. A. Van Ginderachter Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity Blood, April 15, 2008; 111(8): 4233 - 4244. [Abstract] [Full Text] [PDF]

				P.-Y. Pan, G. X. Wang, B. Yin, J. Ozao, T. Ku, C. M. Divino, and S.-H. Chen Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function Blood, January 1, 2008; 111(1): 219 - 228. [Abstract] [Full Text] [PDF]

				S. K. Bunt, L. Yang, P. Sinha, V. K. Clements, J. Leips, and S. Ostrand-Rosenberg Reduced Inflammation in the Tumor Microenvironment Delays the Accumulation of Myeloid-Derived Suppressor Cells and Limits Tumor Progression Cancer Res., October 15, 2007; 67(20): 10019 - 10026. [Abstract] [Full Text] [PDF]

				R. Marhaba, M. Vitacolonna, D. Hildebrand, M. Baniyash, P. Freyschmidt-Paul, and M. Zoller The Importance of Myeloid-Derived Suppressor Cells in the Regulation of Autoimmune Effector Cells by a Chronic Contact Eczema J. Immunol., October 15, 2007; 179(8): 5071 - 5081. [Abstract] [Full Text] [PDF]

				H. Harlin, M. Hanson, C. C. Johansson, D. Sakurai, I. Poschke, H. Norell, K.-J. Malmberg, and R. Kiessling The CD16 CD56bright NK Cell Subset Is Resistant to Reactive Oxygen Species Produced by Activated Granulocytes and Has Higher Antioxidative Capacity Than the CD16+CD56dim Subset J. Immunol., October 1, 2007; 179(7): 4513 - 4519. [Abstract] [Full Text] [PDF]

				P. Berraondo, C. Nouze, X. Preville, D. Ladant, and C. Leclerc Eradication of Large Tumors in Mice by a Tritherapy Targeting the Innate, Adaptive, and Regulatory Components of the Immune System Cancer Res., September 15, 2007; 67(18): 8847 - 8855. [Abstract] [Full Text] [PDF]

				F. B. Thoren, A. I. Romero, S. Hermodsson, and K. Hellstrand The CD16-/CD56bright Subset of NK Cells Is Resistant to Oxidant-Induced Cell Death J. Immunol., July 15, 2007; 179(2): 781 - 785. [Abstract] [Full Text] [PDF]

				F. B. Thoren, A. Betten, A. I. Romero, and K. Hellstrand Cutting Edge: Antioxidative Properties of Myeloid Dendritic Cells: Protection of T Cells and NK Cells from Oxygen Radical-Induced Inactivation and Apoptosis J. Immunol., July 1, 2007; 179(1): 21 - 25. [Abstract] [Full Text] [PDF]

				A. C. Ochoa, A. H. Zea, C. Hernandez, and P. C. Rodriguez Arginase, Prostaglandins, and Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma Clin. Cancer Res., January 15, 2007; 13(2): 721s - 726s. [Abstract] [Full Text] [PDF]

				J. Vieweg, Z. Su, P. Dahm, and S. Kusmartsev Reversal of Tumor-Mediated Immunosuppression Clin. Cancer Res., January 15, 2007; 13(2): 727s - 732s. [Abstract] [Full Text] [PDF]

				N. Mirza, M. Fishman, I. Fricke, M. Dunn, A. M. Neuger, T. J. Frost, R. M. Lush, S. Antonia, and D. I. Gabrilovich All-trans-Retinoic Acid Improves Differentiation of Myeloid Cells and Immune Response in Cancer Patients. Cancer Res., September 15, 2006; 66(18): 9299 - 9307. [Abstract] [Full Text] [PDF]

				M. Munder, H. Schneider, C. Luckner, T. Giese, C.-D. Langhans, J. M. Fuentes, P. Kropf, I. Mueller, A. Kolb, M. Modolell, et al. Suppression of T-cell functions by human granulocyte arginase Blood, September 1, 2006; 108(5): 1627 - 1634. [Abstract] [Full Text] [PDF]

				G. Lizee, L. G. Radvanyi, W. W. Overwijk, and P. Hwu Improving Antitumor Immune Responses by Circumventing Immunoregulatory Cells and Mechanisms. Clin. Cancer Res., August 15, 2006; 12(16): 4794 - 4803. [Abstract] [Full Text] [PDF]

				F. B. Thoren, A. I. Romero, and K. Hellstrand Oxygen Radicals Induce Poly(ADP-Ribose) Polymerase-Dependent Cell Death in Cytotoxic Lymphocytes. J. Immunol., June 15, 2006; 176(12): 7301 - 7307. [Abstract] [Full Text] [PDF]

				M. B. Atkins, D. E. Elder, R. Essner, K. T. Flaherty, T. F. Gajewski, F. G. Haluska, P. Hwu, U. Keilholz, J. M. Kirkwood, J. W. Mier, et al. Innovations and challenges in melanoma: summary statement from the first cambridge conference. Clin. Cancer Res., April 1, 2006; 12(7): 2291s - 2296s. [Abstract] [Full Text] [PDF]

				Z. F. M. Vasconcelos, B. M. dos Santos, J. Farache, T. S. S. Palmeira, R. B. Areal, J. M. T. Cunha, M. A. Barcinski, and A. Bonomo G-CSF-treated granulocytes inhibit acute graft-versus-host disease Blood, March 1, 2006; 107(5): 2192 - 2199. [Abstract] [Full Text] [PDF]

				M. E. Burczynski, R. L. Peterson, N. C. Twine, K. A. Zuberek, B. J. Brodeur, L. Casciotti, V. Maganti, P. S. Reddy, A. Strahs, F. Immermann, et al. Molecular Classification of Crohn's Disease and Ulcerative Colitis Patients Using Transcriptional Profiles in Peripheral Blood Mononuclear Cells J. Mol. Diagn., February 1, 2006; 8(1): 51 - 61. [Abstract] [Full Text] [PDF]

				B. Huang, P.-Y. Pan, Q. Li, A. I. Sato, D. E. Levy, J. Bromberg, C. M. Divino, and S.-H. Chen Gr-1+CD115+ Immature Myeloid Suppressor Cells Mediate the Development of Tumor-Induced T Regulatory Cells and T-Cell Anergy in Tumor-Bearing Host Cancer Res., January 15, 2006; 66(2): 1123 - 1131. [Abstract] [Full Text] [PDF]

				D. S. Goddard, K.-i. Yamanaka, T. S. Kupper, and D. A. Jones Activation of Neutrophils in Cutaneous T-Cell Lymphoma Clin. Cancer Res., December 1, 2005; 11(23): 8243 - 8249. [Abstract] [Full Text] [PDF]

				A. Takahashi, M. G. V. Hanson, H. R. Norell, A. M. Havelka, K. Kono, K.-J. Malmberg, and R. V. R. Kiessling Preferential Cell Death of CD8+ Effector Memory (CCR7-CD45RA-) T Cells by Hydrogen Peroxide-Induced Oxidative Stress J. Immunol., May 15, 2005; 174(10): 6080 - 6087. [Abstract] [Full Text] [PDF]

				A. H. Zea, P. C. Rodriguez, M. B. Atkins, C. Hernandez, S. Signoretti, J. Zabaleta, D. McDermott, D. Quiceno, A. Youmans, A. O'Neill, et al. Arginase-Producing Myeloid Suppressor Cells in Renal Cell Carcinoma Patients: A Mechanism of Tumor Evasion Cancer Res., April 15, 2005; 65(8): 3044 - 3048. [Abstract] [Full Text] [PDF]

				H. Suzuki, D. F. Graziano, J. McKolanis, and O. J. Finn T Cell-Dependent Antibody Responses against Aberrantly Expressed Cyclin B1 Protein in Patients with Cancer and Premalignant Disease Clin. Cancer Res., February 15, 2005; 11(4): 1521 - 1526. [Abstract] [Full Text] [PDF]

				J. W. Kim, E. Wieckowski, D. D. Taylor, T. E. Reichert, S. Watkins, and T. L. Whiteside Fas Ligand-Positive Membranous Vesicles Isolated from Sera of Patients with Oral Cancer Induce Apoptosis of Activated T Lymphocytes Clin. Cancer Res., February 1, 2005; 11(3): 1010 - 1020. [Abstract] [Full Text] [PDF]

				P. C. Rodriguez, D. G. Quiceno, J. Zabaleta, B. Ortiz, A. H. Zea, M. B. Piazuelo, A. Delgado, P. Correa, J. Brayer, E. M. Sotomayor, et al. Arginase I Production in the Tumor Microenvironment by Mature Myeloid Cells Inhibits T-Cell Receptor Expression and Antigen-Specific T-Cell Responses Cancer Res., August 15, 2004; 64(16): 5839 - 5849. [Abstract] [Full Text] [PDF]

				B. A. Pockaj, G. D. Basu, L. B. Pathangey, R. J. Gray, J. L. Hernandez, S. J. Gendler, and P. Mukherjee Reduced T-Cell and Dendritic Cell Function Is Related to Cyclooxygenase-2 Overexpression and Prostaglandin E2 Secretion in Patients With Breast Cancer Ann. Surg. Oncol., March 1, 2004; 11(3): 328 - 339. [Abstract] [Full Text] [PDF]

				S. Kusmartsev, Y. Nefedova, D. Yoder, and D. I. Gabrilovich Antigen-Specific Inhibition of CD8+ T Cell Response by Immature Myeloid Cells in Cancer Is Mediated by Reactive Oxygen Species J. Immunol., January 15, 2004; 172(2): 989 - 999. [Abstract] [Full Text] [PDF]

				Y. Nefedova, M. Huang, S. Kusmartsev, R. Bhattacharya, P. Cheng, R. Salup, R. Jove, and D. Gabrilovich Hyperactivation of STAT3 Is Involved in Abnormal Differentiation of Dendritic Cells in Cancer J. Immunol., January 1, 2004; 172(1): 464 - 474. [Abstract] [Full Text] [PDF]

				M. Terabe, S. Matsui, J.-M. Park, M. Mamura, N. Noben-Trauth, D. D. Donaldson, W. Chen, S. M. Wahl, S. Ledbetter, B. Pratt, et al. Transforming Growth Factor-{beta} Production and Myeloid Cells Are an Effector Mechanism through Which CD1d-restricted T Cells Block Cytotoxic T Lymphocyte-mediated Tumor Immunosurveillance: Abrogation Prevents Tumor Recurrence J. Exp. Med., December 1, 2003; 198(11): 1741 - 1752. [Abstract] [Full Text] [PDF]

				S. Kusmartsev and D. I. Gabrilovich Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species J. Leukoc. Biol., August 1, 2003; 74(2): 186 - 196. [Abstract] [Full Text] [PDF]

				P. C. Rodriguez, A. H. Zea, J. DeSalvo, K. S. Culotta, J. Zabaleta, D. G. Quiceno, J. B. Ochoa, and A. C. Ochoa L-Arginine Consumption by Macrophages Modulates the Expression of CD3{zeta} Chain in T Lymphocytes J. Immunol., August 1, 2003; 171(3): 1232 - 1239. [Abstract] [Full Text] [PDF]

				R. Rozalski, D. Gackowski, K. Roszkowski, M. Foksinski, and R. Olinski The Level of 8-Hydroxyguanine, a Possible Repair Product of Oxidative DNA Damage, Is Higher in Urine of Cancer Patients than in Control Subjects Cancer Epidemiol. Biomarkers Prev., October 1, 2002; 11(10): 1072 - 1075. [Abstract] [Full Text] [PDF]

				S. Jadhav and K. Konstantopoulos Fluid shear- and time-dependent modulation of molecular interactions between PMNs and colon carcinomas Am J Physiol Cell Physiol, October 1, 2002; 283(4): C1133 - C1143. [Abstract] [Full Text] [PDF]

				E. Wieckowski, G.-Q. Wang, B. R. Gastman, L. A. Goldstein, and H. Rabinowich Granzyme B-mediated Degradation of T-Cell Receptor {zeta} Chain Cancer Res., September 1, 2002; 62(17): 4884 - 4889. [Abstract] [Full Text] [PDF]

				S. Cemerski, A. Cantagrel, J. P. M. van Meerwijk, and P. Romagnoli Reactive Oxygen Species Differentially Affect T Cell Receptor-signaling Pathways* J. Biol. Chem., May 24, 2002; 277(22): 19585 - 19593. [Abstract] [Full Text] [PDF]

				S. Jadhav, B. S. Bochner, and K. Konstantopoulos Hydrodynamic Shear Regulates the Kinetics and Receptor Specificity of Polymorphonuclear Leukocyte-Colon Carcinoma Cell Adhesive Interactions J. Immunol., November 15, 2001; 167(10): 5986 - 5993. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schmielau, J. Articles by Finn, O. J. Search for Related Content PubMed PubMed Citation Articles by Schmielau, J. Articles by Finn, O. J.